Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer.

Human pathology - 1 Nov 2020

Hiraoka Nobuyoshi, Nitta Hiroaki, Ohba Akihiro, Yoshida Hiroshi, Morizane Chigusa, Okusaka Takuji, Nara Satoshi, Esaki Minoru, Kishi Yoji, Shimada Kazuaki

Abstract excerpt

Human epidermal growth factor receptor 2 (HER2)-targeted therapy has improved clinical outcomes in patients with HER2-positive breast and gastric cancers, although ineffective or recurrent cases are present. One reason for this is the heterogeneity of HER2 expression in cancer cells. The aim of this study was to investigate the clinicopathological characteristics and HER2 status of patients with biliary tract...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biliary Tract Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Gene Amplification

Share to Genetic Predisposition to Disease

Share to Immunohistochemistry

Share to In Situ Hybridization, Fluorescence

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 32891647
DOI: 10.1016/j.humpath.2020.08.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer.PMID 32891647Read ↗

Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.Semantic proximity Read ↗

ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway.Semantic proximity Read ↗

HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesisSemantic proximity Read ↗

Characterization of EGFR family gene aberrations in cholangiocarcinomaSemantic proximity Read ↗

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.Semantic proximity Read ↗

The Epidemiology of Biliary Tract Cancer and Associated Prevalence of MDM2 Amplification: A Targeted Literature ReviewSemantic proximity Read ↗

HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.Semantic proximity Read ↗

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.Semantic proximity Read ↗

HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment.Semantic proximity Read ↗

HER2 aberrations in cancer: implications for therapy.Semantic proximity Read ↗

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse MalignanciesSemantic proximity Read ↗

Exceptional response to pembrolizumab in HER2-positive gallbladder carcinoma with high tumor mutational burdenSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.